News
-
-
-
-
-
-
-
-
PRESS RELEASE
Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia
Vaderis Therapeutics announces publication of engasertib proof-of-concept study results in The New England Journal of Medicine, showing potential for Hereditary Hemorrhagic Telangiectasia patients -
-
PRESS RELEASE
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire Biopharma Holdings, Inc. submits Pre-IND meeting request to FDA for fast-acting sublingual aspirin formulation to treat acute myocardial infarction, demonstrating rapid action and potential for FDA approval
